Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Malignant progression of preleukemic disordersBlood, 2024-05, Vol.143 (22), p.2245-2255 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023020817 ;PMID: 38498034Full text available |
|
2 |
Material Type: Article
|
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G CommitteeBlood, 2024-05, Vol.143 (22), p.2227-2244 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023476 ;PMID: 38493484Full text available |
|
3 |
Material Type: Article
|
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemiaBlood, 2024-05 [Peer Reviewed Journal]Copyright © 2024 American Society of Hematology. ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2024023890 ;PMID: 38805638Full text available |
|
4 |
Material Type: Article
|
IL-1 in Aging and Pathologies of Hematopoietic Stem CellsBlood, 2024-05 [Peer Reviewed Journal]2024 American Society of Hematology ;Copyright © 2024 American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023105 ;PMID: 38781562Full text available |
|
5 |
Material Type: Article
|
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapyBlood, 2024-05, Vol.143 (21), p.2152-2165 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023381 ;PMID: 38437725Full text available |
|
6 |
Material Type: Article
|
Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemiaBlood, 2024-05, Vol.143 (21), p.2166-2177 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023022455 ;PMID: 38437728Full text available |
|
7 |
Material Type: Article
|
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domainBlood, 2024-05, Vol.143 (21), p.2178-2189 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023120 ;PMID: 38394665Full text available |
|
8 |
Material Type: Article
|
Smoldering multiple myeloma: taking the narrow over the wide path?Blood, 2024-05, Vol.143 (20), p.2025-2028 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2024023880 ;PMID: 38427775Full text available |
|
9 |
Material Type: Article
|
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231Blood, 2024-05, Vol.143 (20), p.2053-2058 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023021184 ;PMID: 38457359Full text available |
|
10 |
Material Type: Article
|
Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosisBlood, 2024-05, Vol.143 (20), p.2089-2098 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023021265 ;PMID: 38271661Full text available |
|
11 |
Material Type: Article
|
Platelet dysfunction reversal with cold-stored vs room temperature–stored platelet transfusionsBlood, 2024-05, Vol.143 (20), p.2073-2088 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023022593 ;PMID: 38427589Full text available |
|
12 |
Material Type: Article
|
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myelomaBlood, 2024-05, Vol.143 (20), p.2029-2036 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023597 ;PMID: 38394666Full text available |
|
13 |
Material Type: Article
|
How I treat challenging transfusion cases in sickle cell diseaseBlood, 2024-05 [Peer Reviewed Journal]2024 American Society of Hematology ;Copyright © 2024 American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023648 ;PMID: 38728382Full text available |
|
14 |
Material Type: Article
|
let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switchingBlood, 2024-05, Vol.143 (19), p.1980-1991 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023399 ;PMID: 38364109Full text available |
|
15 |
Material Type: Article
|
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionBlood, 2024-05, Vol.143 (19), p.1931-1936 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023023096 ;PMID: 38364112Full text available |
|
16 |
Material Type: Article
|
Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasisBlood, 2024-05, Vol.143 (19), p.1937-1952 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023022666 ;PMID: 38446574Full text available |
|
17 |
Material Type: Article
|
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphomaBlood, 2024-05, Vol.143 (19), p.1953-1964 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;ISSN: 1528-0020 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023022241 ;PMID: 38237141Full text available |
|
18 |
Material Type: Article
|
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigensBlood, 2024-05, Vol.143 (18), p.1856-1872 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023022343 ;PMID: 38427583Full text available |
|
19 |
Material Type: Article
|
Kewan T, Bahaj W, Durmaz A, et al. Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood. 2023;141(14):1768-1772Blood, 2024-05, Vol.143 (18), p.1879-1879 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2024024464 ;PMID: 38696199Full text available |
|
20 |
Material Type: Article
|
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancyBlood, 2024-05, Vol.143 (18), p.1825-1836 [Peer Reviewed Journal]2024 American Society of Hematology ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2024 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2023019706 ;PMID: 38211332Full text available |